Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

View ORCID ProfileRaches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Samiran Panda, Priya Abraham, Nivedita Gupta, Krishna Ella, Balram Bhargava, Krishna Mohan Vadrevu
doi: https://doi.org/10.1101/2020.12.21.20248643
Raches Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raches Ella
  • For correspondence: rachesella@gmail.com
Siddharth Reddy
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harsh Jogdand
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vamshi Sarangi
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunda Ganneru
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Prasad
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dipankar Das
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dugyala Raju
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Usha Praturi
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gajanan Sapkal
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Yadav
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prabhakar Reddy
4Nizams Institute of Medical Sciences, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Verma
5Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandramani Singh
6All India Institute of Medical Sciences, Patna, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagar Vivek Redkar
7Redkar Hospital, Dargalim, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Sekhar Gillurkar
8Gillurkar Hospital, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jitendra Singh Kushwaha
9Prakhar Hospital, Kanpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satyajit Mohapatra
10SRM Hospital and Research Centre, Kattankulathur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bhate
11Jeevan Rekha Hospital, Belgaum, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Rai
12All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samiran Panda
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Abraham
2Indian Council of Medical Research-National Institute of Virology, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nivedita Gupta
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balram Bhargava
3Indian Council of Medical Research, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Mohan Vadrevu
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg) formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, we reported findings from a phase 1 (vaccination regimen on days 0 and 14) randomised, double-blind trial on the safety and immunogenicity of three different formulations of BBV152 and one control arm containing Algel (without antigen). Two formulations were selected for the phase 2 (days 0 and 28) study. Here, we report interim findings of a controlled, randomised, double-blind trial on the immunogenicity and safety of BBV152: 3 µg and 6 µg with Algel-IMDG.

Methods We conducted a double-blind, randomised, multicentre, phase 2 clinical trial to evaluate the immunogenicity and safety of BBV152. A total of 380 healthy children and adults were randomised to receive two vaccine formulations (n=190 each) with 3 µg with Algel-IMDG and 6 µg with Algel-IMDG. Two intramuscular doses of vaccines were administered (four weeks apart). Participants, investigators, and laboratory staff were blinded to the treatment allocation. The primary outcome was seroconversion (≥4-fold above baseline) based on wild-type virus neutralisation (PRNT50). Secondary outcomes were reactogenicity and safety. Cell-mediated responses were evaluated. A follow-up blood draw was collected from phase 1 participants at day 104 (three months after the second dose).

Findings Among 921 participants screened between Sep 7-13, 2020, 380 participants were randomised to the safety and immunogenicity population. The PRNT50 seroconversion rates of neutralising antibodies on day 56 were 92·9% (88·2, 96·2) and 98·3% (95·1, 99·6) in the 3 µg and 6 µg with Algel-IMDG groups, respectively. Higher neutralising titres (2-fold) were observed in the phase 2 study than in the phase 1 study (p<0.05). Both vaccine groups elicited more Th1 cytokines than Th2 cytokines. After two doses, the proportion (95% CI) of solicited local and systemic adverse reactions were 9.7% (6·9, 13·2) and 10.3% (7·4, 13·8) in the 3 µg and 6 µg with Algel-IMDG groups, respectively. No significant difference was observed between the groups. No serious adverse events were reported in this study. Phase 1 follow-up immunological samples at day 104 showed seroconversion in 73·5% (63·6, 81·9), 81·1% (71·4, 88·1), and 73·1% (62·9, 81·8) of individuals in the 3 µg with Algel-IMDG, 6 µg with Algel-IMDG, and 6 µg with Algel groups, respectively.

Interpretation In the phase 1 trial, BBV152 produced high levels of neutralising antibodies that remained elevated in all participants three months after the second vaccination. In the phase 2 trial, BBV152 led to tolerable safety outcomes and enhanced humoral and cell-mediated immune responses. The safety profile of BBV152 is noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates. The 6 µg Algel-IMDG formulation was selected for the phase 3 efficacy trial.

Funding This work was supported and funded by Bharat Biotech International Limited.

Clinicaltrials.gov: NCT04471519

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Clinicaltrials.gov: NCT04471519

Funding Statement

The study was funded by Bharat Biotech.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Details and individual names of the Ethics Committee members were not provided to the authors. Nizams Institute of Medical Science, Hyderabad, Telangana ECR/303/INST/AP/2013/RR-19 All India Institute of Medical Science, New DelhiECR/547/INST/DL/2014/RR-17 PGIMS, Rohtak, Haryana ECR/293/Inst/HR/2013/RR-19 All India Institute of Medical Science, PatnaECR/1387/INST/BR/2020 Redkar Hospital & Research Centre, GoaECR/902/INST/GA/2018 Jeevan Rekha Hospital, Belgaum, KarnatakaECR/1242/INST/KA/2019 Gillukar Multispecialty Hospital, NagpurECR/1374/INST/MH/2020 Prakhar Hospital, Kanpur, Uttar PradeshECR/1017/INST/UP/2017 SRM Medical College Hospital & Research Centre, Chennai Tamil Nadu ECR/431/INST/TL/2013/RR-19

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The study protocol is provided in the Supplemental Appendix Individual participant (de-identified) data will be made available when the trial is complete upon request directed to the corresponding author, after the approval of a proposal, data can be shared through a secure online platform.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Samiran Panda, Priya Abraham, Nivedita Gupta, Krishna Ella, Balram Bhargava, Krishna Mohan Vadrevu
medRxiv 2020.12.21.20248643; doi: https://doi.org/10.1101/2020.12.21.20248643
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Samiran Panda, Priya Abraham, Nivedita Gupta, Krishna Ella, Balram Bhargava, Krishna Mohan Vadrevu
medRxiv 2020.12.21.20248643; doi: https://doi.org/10.1101/2020.12.21.20248643

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (143)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (71)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4881)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (680)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5368)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (691)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (36)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1825)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (139)
  • Respiratory Medicine (255)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)